Dr Frédéric Triebel
Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001) and serves as the Scientific and Medical Director at Immutep since 2004. Before starting Immutep, he was Professor in Immunology at ParisUniversity. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while being also involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996.
First trained as a clinical haematologist, Dr. Triebel holds a Ph.D. in immunology (ParisUniversity) and successfully developed several research programs in immunogenetics, leading to 141 publications and 16 patents.
Immutep has been acquired by Prima Biomed Ltd in December 201